Drs. Susan Block, Atul Gawande and Rachelle Bernacki were mentioned for the randomized study performed at Dana-Farber examining how closely the wishes of a group of the sickest patients are honored during end-of-life care.
Dr. Anthony Letai led a study showing a new technique that can predict which specific drug will be most effective in treating various types of cancer tumors.
Dr. Paul Richardson commented on the US Food and Drug Administration’s decision to expand the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients with newly diagnosed multiple myeloma.
Dr. Lawrence Shulman wrote about his work in Rwanda and providing access to life-saving advances in cancer treatment through the collaborations of the Rwandan Ministry of Health, Partners in Health, and Dana-Farber.
Dana-Farber physicians including Dr. Barrett Rollins and Dr. Kenneth C. Anderson talked about the next generation of cancer-fighting drugs at the 14th annual Breakfast with the Doctors in Palm Beach.
Dr. Joanne Wolfe, director of the Pediatric Advanced Care Team, or PACT, at Dana Farber/Boston Children’s Cancer and Blood Disorders Center, commented on the challenges of pediatric palliative care.
Dr. James Bradner and his team continue to work on the JQ1 molecule, which tricks the body into forgetting how to make sperm.
Dr. Kwok-Kin Wong commented on the use of EZH2 inhibitors in lung cancer as needing more rationale in preclinical studies.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: